Asston Pharmaceuticals Limited has scheduled an Extraordinary General Meeting (EGM) on July 31, 2026, to seek shareholder approval for the preferential allotment of up to 24,10,431 equity shares to non-promoters, aiming to raise ₹27.72 crore. The issuance, priced at ₹115 per share including a premium of ₹105, will fund working capital requirements, debt repayment, and capital expenditure. The meeting will be conducted via Video Conferencing or Other Audio Visual Means at 12:30 PM.

The preferential issue is entirely directed at persons belonging to the Non-Promoter category. Vijay Rathee is set to emerge as a significant shareholder with a proposed allocation of 13,17,391 shares, representing 12.06% of the post-issue equity capital. Vijaylaxmi Infra Projects Private Limited will receive 7,82,608 shares, accounting for 7.16% of the total equity capital post-allotment. Other public investors, including Shreevardhan Nitin Tupe and Yashvardhan Nitin Tupe, will also increase their stakes through this issuance.

Utilization of Funds

The company plans to utilize the net proceeds of the issue for specific corporate objectives. The funds will be deposited in a scheduled commercial bank until utilized.

Post-Issue Shareholding Pattern

The following table illustrates the proposed shareholding post-allotment, assuming full subscription.

The total promoter holding will decrease from 50.66% to 39.48% post-issue, while public shareholding will increase to 60.52%. The Board of Directors approved the issuance on July 02, 2026.

EGM and E-Voting Details

The 2nd EGM for FY 2026-27 will be held on Friday, July 31, 2026, at 12:30 P.M. through Video Conferencing or Other Audio Visual Means. Remote e-voting commences on Tuesday, July 28, 2026, at 9:00 A.M. and concludes on Thursday, July 30, 2026, at 5:00 P.M. Members holding shares as on the cut-off date of July 24, 2026, are eligible to vote. The notice was published in the Financial Express and Mumbai Lakshwadeep on July 10, 2026.

Asston Pharmaceuticals Limited has scheduled a board meeting on July 2, 2026, to consider a proposal for raising funds. The board will evaluate various methods for the capital raise, including a preferential issue, subject to necessary regulatory and statutory approvals as well as shareholder authorization.

The decision to explore fund-raising options comes as the company seeks to bolster its financial resources. The preferential issue, if approved, would require the consent of the shareholders of the company. The meeting agenda includes reviewing these proposals to determine the most suitable path forward for the capital infusion.

In conjunction with the board meeting, the company has announced the closure of the trading window for its securities. This measure is in line with the Company's Code of Conduct framed under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The restriction is effective from June 24, 2026, and will remain in place until July 4, 2026, inclusive of both dates.

During this period, all connected persons and designated persons are advised not to trade in the listed securities or any proposed to be listed securities of the company. This step is intended to ensure compliance with insider trading norms and maintain market integrity ahead of the board's decision.

The intimation was submitted to BSE Limited pursuant to Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015. Rishi Upadhaya, Company Secretary & Compliance Officer, signed the disclosure on behalf of the Board of Directors.